Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas

Oncology Reports

Volumn 18, Issue 1, 2007, Pages 249-252

  Orzan, Francesca ^a   Terreni, Maria Rosa ^b   Longoni, Mauro ^a   Boari, Nicola ^b   Mortini, Pietro ^c   Doglioni, Claudio ^b   Riva, Paola ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Imatinib mesylate; KIT; PDGFR; Skull base chordoma

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; MESSENGER RNA; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; RNA; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CHORDOMA; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKULL BASE TUMOR; STROMA CELL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHORDOMA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SKULL BASE NEOPLASMS; STROMAL CELLS;

EID: 34548017050     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.1.249     Document Type: Article

References (8)

1. Crockard HA, Steel T, Plowman N, Singh A, Crossman J, Revesz T, Holton JL and Cheeseman A: A multidisciplinary team approach to skull base chordomas. J Neurosurg 95: 175-183, 2001. (Pubitemid 32799737)
2. Azzarelli A, Quagliuolo V, Cerasoli S, Zucali R, Bignami P, Mazzaferro V, Dossena G and Gennai L: Chordoma: natural history and treatment results in 33 cases. J Surg Oncol 37: 185-191, 1988. (Pubitemid 18095868)
3. Chugh R, Dunn R, Zalupski MM, Biermann JS, Sondak VK, Mace JR, Leu KM, Chandler WF and Baker LH: Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 23: 3597-3604, 2005.
4. Scimeca PG, James-Herry AG, Black KS, Kahn E and Weinblatt ME: Chemotherapeutic treatment of malignant chordoma in children. J Pediatr Hematol Oncol 18: 237-240, 1996. (Pubitemid 26163488)
5. York JE, Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA and Gokaslan ZL: Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 44: 74-79, 1999.
6. Casali PG, Messina A, Stacchiotti S, Tamburini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertuelli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pienotti MA and Pilotti S: Imatinib mesylate in chordoma. Cancer 101: 2086-2097, 2004. (Pubitemid 39425386)
7. Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C and Donner DD: Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 25: 2060-2069, 2006.
8. Bhowmick NA, Neilson EG and Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337, 2004. (Pubitemid 39551661)